Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscription Services
Promote Your Event
Submission Forms
Place an Ad
Weather
News
Local News
Sports
Entertainment
Obituaries
Photos
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Items For Sale
Jobs
Pets
Auctions, Estate & Garage Sales
Place an ad
Services
Community
Personals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Biodesix, Inc.
Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights
March 06, 2023
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Participate at Cowen’s 43rd Annual Healthcare Conference
February 28, 2023
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
February 21, 2023
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® Test
December 19, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors
December 16, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Ranked Top Proteomics Solutions Company by Life Sciences Review Magazine
December 12, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
November 21, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock
November 17, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces Proposed Public Offering of Common Stock
November 16, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million
November 16, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 10, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces Third Quarter 2022 Results and Highlights
November 03, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022
October 20, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing Solutions
October 17, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs
October 12, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces Preliminary Revenue for Third Quarter 2022
October 11, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Participate in Two Upcoming Investor Conferences in September
September 06, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Named a Top 100 Healthcare Technology Company of 2022
August 09, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces Second Quarter 2022 Results and Highlights
August 04, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference
August 03, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors
July 20, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022
July 19, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Obtains Medicare Coverage for the Nodify CDT® Lung Nodule Test
June 07, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces Research Agreement with Top US Cancer Center
June 03, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Present at the 42nd Annual William Blair Growth Stock Conference
June 01, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to be Presented at ATS 2022 International Conference
May 12, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Announces First Quarter 2022 Results and Highlights
May 11, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix to Report First Quarter 2022 Financial Results on May 11, 2022
April 27, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan
April 11, 2022
From
Biodesix, Inc.
Via
Business Wire
Tickers
BDSX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.